PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ROZANOLIXIZUMAB IN ADULT PARTICIPANTS WITH OCULAR MYASTHENIA GRAVIS

A Drug Utilisation Study of Fenfluramine in Europe

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo inPatients with Primary Progressive Multiple Sclerosis

Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Therapy in Patients with Lennox-Gastaut Syndrome

Eficacia y tolerabilidad del lasmiditán en vida real.

Estudio Transversal No Intervencionista Para Evaluar La Calidad De Vida Y El Impacto General De La Enfermedad En Adolescentes Y Adultos Con Diagnóstico De Trastorno Asociado A Anticuerpos Contra La Glicoproteína De Oligodendrocitos De Mielina En España

A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Usnoflast administered to adult subjects with Amyotrophic Lateral Sclerosis (ALS)

A Master Protocol for an Exploratory Phase 2a Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

A Double-blind, Randomized, Multi-Center Study Investigating Efficacy

and Safety of two Different Dosages of Intravenous Human Normal

Immune Globulin (IGIV) 10% in Subjects with Chronic Inflammatory

Demyelinating Polyneuropathy (CIDP)

A Multi-Center Double Blind Placebo Controlled Phase Ii Study Evaluating

The Safety, Pharmacokinetics, Pharmacodynamics And Efficacy Of

Ro7268489, A Monoacylglycerol Lipase Inhibitor, As Add-On Therapy To

Ocrelizumab In Participants With Progressive Forms Of Multiple Sclerosis

A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in

Participants with Early Parkinson’s Disease

A randomized, double-blind, placebo-controlled study to evaluate the

efficacy and safety of remibrutinib in patients with secondary progressive

multiple sclerosis

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of

Fenfluramine Hydrochloride For The Treatment Of Females With Rett

Syndrome

Observational study evaluating subcutaneous LDp/CDp Solution for

Infusion Effectiveness on Sleep Disturbances in Advanced Parkinson’s

Disease

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-

Period Study to Assess the Efficacy and Safety of a New Formulation of

Oral Cladribine Compared with Placebo in Participants with Generalized

Myasthenia Gravis

A Phase IIb Randomized, Double-blind, Placebo-controlled, Multi- Dose Study to Evaluate the Effects of PHENOGENE-1a (Cromolyn) as an Adjuvant Treatment in Subjects with Mild to Moderate Amyotrophic Lateral Sclerosis (ALS).

A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early parkinson’s disease

Un estudio de fase 1/2a de escalamiento de dosis para evaluar la seguridad, tolerabilidad, farmacocinética y farmacodinámica de aro-dm1 en sujetos con distrofia miotónica tipo 1 que tienen ≥18 a ≤65 años

A phase 2, randomized, observer-blind, placebo-controlled, dose-ranging study of mRNA-1195 intramuscular injection in participants 18 to ≤55 years of age with early MS

A randomized, phase III, open label study to investigate pharmacokinetics, safety, radiological and clinical effects of subcutaneous frexalimab (SAR441344) compared to intravenous frexalimab in adult participants with multiple sclerosis.

An open-label, multi-center, phase 1/2 study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with progressive Multiple Sclerosis (PMS)